A pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard solution for comprehensive management of liver health.
FibroScan® is recognized worldwide as the reference for liver fibrosis and liver steatosis assessment with more than 5 380+ peer-reviewed publications and 210+ international guidelines.
Echosens has made FibroScan® available in over 127 countries through its network of subsidiaries in Europe (Germany, Spain, UK, Italy), the United States and China (Shanghai, Shenzen and Hong Kong), enabling millions of liver examinations worldwide.
Echosens is shaping the future of liver health. As a high-tech company, its connected solutions and services empower medical professionals to manage liver health for simpler, faster and better patient care.
In today’s digital healthcare environment and the silent epidemic of fatty liver disease (MASLD-MASH), Echosens is pursuing its international expansion and aims to make the liver check-up part of the health routine for at-risk patients, particularly people living with diabetes.